Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,264 | $2,355 | $2,237 | $2,289 |
| % Growth | -3.9% | 5.2% | -2.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2,264 | $2,355 | $2,237 | $2,289 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $2 | $52 | $177 | $200 |
| G&A Expenses | $237 | $250 | $227 | $183 |
| SG&A Expenses | $237 | $250 | $227 | $183 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $732 | $561 | $1,526 | $476 |
| Operating Expenses | $971 | $862 | $1,930 | $859 |
| Operating Income | $1,292 | $1,492 | $307 | $1,431 |
| % Margin | 57.1% | 63.4% | 13.7% | 62.5% |
| Other Income/Exp. Net | $38 | $208 | -$77 | -$190 |
| Pre-Tax Income | $1,331 | $1,700 | $230 | $1,241 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $859 | $1,135 | $43 | $620 |
| % Margin | 37.9% | 48.2% | 1.9% | 27.1% |
| EPS | 1.92 | 2.54 | 0.1 | 1.49 |
| % Growth | -24.4% | 2,440% | -93.3% | – |
| EPS Diluted | 1.91 | 2.53 | 0.1 | 1.49 |
| Weighted Avg Shares Out | 446 | 448 | 438 | 415 |
| Weighted Avg Shares Out Dil | 594 | 603 | 438 | 415 |
| Supplemental Information | – | – | – | – |
| Interest Income | $47 | $72 | $78 | $54 |
| Interest Expense | $226 | $187 | $188 | $166 |
| Depreciation & Amortization | $0 | $0 | $6 | $23 |
| EBITDA | $1,556 | $1,887 | $424 | $1,430 |
| % Margin | 68.8% | 80.2% | 18.9% | 62.5% |